The U.S. Food and Drug Administration has proposed on Apr. 7 a series of regulatory reforms for its 2027 budget, including making the rare pediatric disease priority review voucher program permanent and introducing a new pathway to simplify the start of Phase 1 clinical trials.
The FDA's proposal comes as President Donald Trump has allotted $7.23 billion for the agency in 2027, marking a $232 million increase from the previous year. This funding boost stands out against an overall Department of Health and Human Services budget reduction of 12% to $111.1 billion.
FDA Commissioner Marty Makary said in his letter accompanying the proposal that these changes are intended to move the agency "from a reactionary system to a proactive system." He outlined plans for new pathways that would expedite drug development, enhance national security, and promote "radical transparency."
A key reform is making permanent the rare pediatric disease priority review voucher program, which was first enacted in 2012 to encourage companies to develop treatments for rare childhood diseases by offering expedited product reviews as rewards. The program has faced interruptions due to lapses in Congressional renewal, most recently sunsetting at the end of 2024 before being restarted in September 2025.
Another major initiative is a proposed "clinical trial notification pathway" aimed at reducing duplicative requirements associated with launching Phase 1 trials under the current Investigational New Drug application process. The FDA said this alternative would help smaller companies by lowering barriers while maintaining safety standards and could reduce costs for drug development.
Makary previously raised concerns about regulatory burdens driving early-stage studies overseas and suggested adjustments such as lower user fees for companies conducting Phase 1 studies domestically versus higher fees abroad.
Additionally, the FDA plans to expand its rejection disclosures by amending regulations so it can share information on deficiencies found in rejected drugs or biologics applications. Last year, more than 200 complete response letters were released publicly; moving forward, these rejections will be made available in real time.
